Abstract
68Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor–expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history; the histopathology and biomarker information; and the grade, stage, and prior imaging results. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false-positive results. This article provides a guide to the performance and interpretation of 68Ga-DOTATATE PET/CT and describes its role in the diagnostic algorithm of neuroendocrine neoplasms and its overall utility in their management.
Footnotes
Published online Aug. 17, 2017.
Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the role of 68Ga-DOTATATE in neuroendocrine tumor management, (2) the interpretation of 68Ga-DOTATATE PET/CT images, and (3) the integration of 68Ga-DOTATATE PET/CT in the diagnostic and management algorithm for neuroendocrine tumors.
Financial Disclosure: Dr. Bodei is a consultant/advisor for Ipsen and AAA Pharmaceutical, and Dr. Herrmann is a consultant/advisor for Ipsen, Curium, and Sofie Biosciences and an investigator for AAA Pharmaceutical. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest.
CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA category 1 credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through November 2020.
- © 2017 by the Society of Nuclear Medicine and Molecular Imaging.